Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

U.S. Multiple Sclerosis Markets

Published by: Frost & Sullivan

Published: Sep. 25, 2007 - 77 Pages


Table of Contents


1. Executive Summary

1. Executive Summary

1. Introduction




2. Market Introduction

1. Introduction

1. Multiple Sclerosis

2. Scope and Segmentation

3. Research Methodology

2. Disease Overview

1. Causes of Multiple Sclerosis

2. Classification of Multiple Sclerosis

3. Treatment Options

3. Market Overview

1. Market Engineering Measurements

2. Market Trends




3. Market Analysis

1. Product Analysis

1. Interferons

2. Copaxone

3. Tysabri

4. Novantrone

5. Pipeline Drugs

2. Patient Forecasts

1. Total Patient Forecasts

2. Patient Forecast by Product

3. Revenue Forecasts

1. Total Market Revenue Forecasts

2. Revenue Forecasts by Product

4. Competitive Analysis

1. Competitive Structure

2. Company Market Share

5. Competitve Metrics

1. Methodology and Metrics

2. Biogen Idec

3. Teva Pharmaceuticals

4. EMD Serono

5. Bayer Schering Pharma

6. Emerging Companies




4. Decision Support Databases

1. Demographic Indicators

1. Total Population

2. Market Indicators

1. World Multiple Sclerosis Prevalence

2. U.S. Multiple Sclerosis Prevalence

3. U.S. Multiple Sclerosis Incidence

4. Pharmaceutical R&D Expenditure





List of Figures




Chapter 3


Multiple Sclerosis Market: Product Analysis - Interferons (U.S.), 2006

Multiple Sclerosis Market: Phase III Pipeline Analysis (U.S.), 2006

Multiple Sclerosis Market: Phase I and II Pipeline (U.S.), 2006

Multiple Sclerosis Market: Patient Forecasts (U.S.), 2003-2013

Multiple Sclerosis Market: Potential versus Treated Patients Forecasts (U.S.), 2003-2013

Multiple Sclerosis Market: Patient Share by Product (U.S.), 2003-2013

Multiple Sclerosis Market: Revenue Forecasts (U.S.), 2003-2013

Multiple Sclerosis Market: Average Annual Cost of Therapy per Patient Forecasts (U.S.), 2003-2013

Multiple Sclerosis Market: Revenue Share by Product Type Forecasts (U.S.), 2003-2013

Multiple Sclerosis Market: Revenues Forecasts by Product (U.S.), 2003-2013

Multiple Sclerosis Market: Revenue Share Forecasts by Product (U.S.), 2003-2013

Multiple Sclerosis Market: Competitive Structure (U.S.), 2006

Multiple Sclerosis Market: Revenue Share by Major Market Participants (U.S.), 2004-2006

Multiple Sclerosis Market: Patient Share by Major Market Participants (U.S.), 2004-2006

Multiple Sclerosis Market: Major Market Participants Competitive Metrics (U.S.), 2007

Multiple Sclerosis Market: Emerging Market Participants Competitive Metrics (U.S.), 2007

Abstract

Research Overview

This Frost & Sullivan research service titled U.S. Multiple Sclerosis Markets provides detailed market forecasts, pipeline analysis, and competitive metrics. In this research, Frost & Sullivan's expert analysts thoroughly examine the following markets: pharmaceuticals, biotechnology, and specialty pharmaceuticals.

Market Sectors

Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:

  • Pharmaceuticals
  • Biotechnology
  • Specialty pharmaceuticals
Technologies

The following technologies are covered in this research:
  • Interferons
  • Immunosuppressants
  • Immunomodulators
Market Overview

Underserved Multiple Sclerosis Therapy Market Gets a Lifeline with the Development of Numerous Treatment Options

Healthcare companies across all tiers of competition are beginning to sit up and take notice of the U.S. multiple sclerosis (MS) market, following a spate of innovations in therapies. Big pharma, specialty pharma, niche pharma, biotechnology, and start-up companies could soon fill the vacuum created by the lack of an outstanding treatment option. "The pipeline for MS is robust, with a strong mix of early stage and late stage products, offering improved methods of treating and possibly, curing the disease," says the analyst of this research service.

The market is expected to experience a boom between 2007 and 2013 with the launch of oral therapies as well as improved versions of interferons. Innovations will stand market participants in good stead, since healthcare providers are hoping to improve the standard of care and patient compliance. Multiple sclerosis treatment could go through a paradigm change due to the introduction of these therapies, since patients who failed interferon therapy or quit treatment due to side effects will still have an array of options, unlike earlier.

Wide-ranging Therapies in the Pipeline Address Various Types of Multiple Sclerosis

"The pipeline for MS treatments includes a variety of innovative treatment options ranging from oral therapies to vaccine-based treatments," notes the analyst. "While traditional injection-based interferon therapies continue to remain the cornerstone of treatment, the next generation of therapies in development is dominated by oral formulations that cater predominantly to the relapsing remitting type of MS."

The unmet medical needs in primary progressive MS (PPMS) and secondary progressive MS (SPMS) segments are opening up significant market expansion opportunities for participants. Vendors are testing existing products for label expansion into other market segments, while simultaneously working on launching innovative therapies for the same purpose.

Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options
See related reports or call the number above for help from a research specialist.


advertise with us

 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2008